| 1 |
Swe TM, Johnson DC, Mar HT, Thit P, Homan T, Chu CM, Mon PE, Thwe TT, Soe KP, Ei WLSS, Tun NL, Lwin KZ, Karakozian H, Aung KS, Nguyen A, Ciglenecki I, Tamayo N, Loarec A. Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study. Health Sci Rep 2023;6:e1119. [PMID: 36819986 DOI: 10.1002/hsr2.1119] [Reference Citation Analysis]
|
| 2 |
Sabry N, Kamel AM, Cordie A, Esmat G. Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation. Expert Opin Pharmacother 2023;24:159-70. [PMID: 36369914 DOI: 10.1080/14656566.2022.2145883] [Reference Citation Analysis]
|
| 3 |
Boeke CE, Adesigbin C, Adisa O, Agwuocha C, Akanmu MM, Anartati A, Aung KS, Azania A, Bello Nabe R, Budiman A, Chan Y, Chawla U, Fatchanuraliyah, Fernandes O, Grover GS, Naing TS, Ngo D, Ramers CB, Regan S, Sindhwani S, Tandy G, Tint K, Nguyen KV, Witschi M, McClure C. Patient outcomes in public sector hepatitis C treatment programmes: a retrospective cohort analysis across five low- and middle-income countries. BMJ Open 2022;12:e062745. [PMID: 36576192 DOI: 10.1136/bmjopen-2022-062745] [Reference Citation Analysis]
|
| 4 |
Draper BL, Htay H, Pedrana A, Yee WL, Howell J, Pyone Kyi K, Naing W, Sanda Aung K, Markby J, Easterbrook P, Bowring A, Aung W, Sein YY, Nwe N, Myint KT, Shilton S, Hellard M. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar. Liver Int 2021;41:2578-89. [PMID: 34153155 DOI: 10.1111/liv.14983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 5 |
Boeke CE, Adesigbin C, Agwuocha C, Anartati A, Aung HT, Aung KS, Grover GS, Ngo D, Okamoto E, Ngwije A, Nsanzimana S, Sindhwani S, Singh G, Sun LP, Kinh NV, Waworuntu W, McClure C. Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination. BMJ Glob Health. 2020;5. [PMID: 33328200 DOI: 10.1136/bmjgh-2020-003767] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 6 |
Flower B, McCabe L, Le Ngoc C, Le Manh H, Le Thanh P, Dang Trong T, Vo Thi T, Vu Thi Kim H, Nguyen Tat T, Phan Thi Hong D, Nguyen Thi Chau A, Dinh Thi T, Tran Thi Tuyet N, Tarning J, Kingsley C, Kestelyn E, Pett SL, Thwaites G, Nguyen Van VC, Smith D, Barnes E, Ansari MA, Turner H, Rahman M, Walker AS, Day J, Cooke GS. High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infect Dis 2021;8:ofab267. [PMID: 34337093 DOI: 10.1093/ofid/ofab267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Chan H, Hassali MA, Md Said R, Omar H, Abd Mutalib NA, De Rozario FW, Abu Hassan MR. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.113226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Zhang M, O'Keefe D, Craig J, Samley K, Bunreth V, Jolivet P, Balkan S, Marquardt T, Dousset JP, Le Paih M. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system. Lancet Gastroenterol Hepatol 2021;6:371-80. [PMID: 33743883 DOI: 10.1016/S2468-1253(21)00012-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
